Tazverik’s withdrawal from the global market in March 2026 has now claimed a second casualty — and the mechanism matters more than the molecule. Fulcrum Therapeutics is shutting down pociredir, its oral EED inhibitor, after FDA concluded on May 28 that any agent targeting the PRC2 complex carries equivalent secondary malignancy risk regardless of which subunit it engages. That single regulatory judgment effectively forecloses an entire mechanistic class, not just one compound.
The scientific argument Fulcrum made was reasonable: EED and EZH2 perform distinct biological roles within PRC2, so extrapolating tazemetostat’s oncology signal to an EED inhibitor requires assumptions Fulcrum contested. FDA reviewed that position and rejected it, citing pociredir’s own preclinical malignancy observations as corroborating evidence. With no viable path forward and a PIONEER Phase 1b that had actually delivered — dose-dependent fetal hemoglobin elevation, pan-cellular HbF induction, improvements in hemolysis markers, no treatment-related serious adverse events through three months — the discontinuation is a regulatory judgment call, not a clinical failure. That distinction will matter to whoever eventually dissects what PRC2 inhibition can and cannot do in hematology.
What’s left is a company with $333.3 million in cash as of March 31, 2026, no lead program, and a board-authorized strategic review covering merger, acquisition, business combination, or asset transactions. Fulcrum has committed to cutting operating expenses and preserving capital while that process runs. The cash balance is substantial for a clinical-stage company with nothing in the clinic — it transforms Fulcrum from a drug developer into an acquisition target carrying a clean balance sheet and a proprietary gene-expression modulation platform that, despite this setback, identified a genuinely differentiated mechanism.
The number to watch is how quickly that $333 million attracts a buyer. At Fulcrum’s recent market capitalization, the cash alone arguably exceeds the stock price, which means any acquirer is effectively getting the platform and remaining assets at a discount or for free. Strategic review processes at companies in this financial position rarely drag past two quarters before a transaction materializes — the board’s decision not to set a timeline is standard language, not a signal of complexity. The real question is whether any acquirer believes the FDA’s class-level PRC2 ruling is permanent, or simply the regulatory environment of this moment.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
